Nebius Group NV's shares rise on strong power contract goals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2024
0mins
Source: MarketWatch
Nebius Group NV's shares increased by 5.01% as the stock crossed above the 5-day SMA, reflecting positive momentum in the market. The surge is attributed to the company's ambitious target of securing 2.5 gigawatts of contracted power by 2026, significantly up from its previous goal of 1 gigawatt. This strategic move is expected to enhance its competitiveness in the AI infrastructure sector and is supported by substantial revenue growth, including a 355% year-over-year increase in third-quarter revenues to $146 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NBIS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NBIS
Wall Street analysts forecast NBIS stock price to fall
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 214.770
Low
130.00
Averages
164.20
High
211.00
Current: 214.770
Low
130.00
Averages
164.20
High
211.00
About NBIS
Nebius Group NV is a Netherlands-based infrastructure company operating in the technology industry. The Company is engaged in developing a portfolio of artificial intelligence-related technology assets. It is involved in creating an artificial intelligence-centric player to integrate the essential elements of artificial intelligence development with infrastructure, data and advisory globally. It offers products and services such as a cloud platform for artificial intelligence-related workloads, development team services for autonomous vehicles, development of generative artificial intelligence. Nebius builds full-stack infrastructure to service the growth of the global AI industry, including GPU clusters, cloud platforms and tools and services for developers. Company is developing three other businesses that operate under their own brands: Toloka AI, TripleTen and Avride.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Absci Corp: The Future Potential of Drug Discovery
- Innovative Drug Discovery Platform: Absci Corp utilizes its Integrated Drug Creation platform to leverage generative AI for designing potential protein-based drugs, aiming to rapidly transform disease targets into viable biologic drug sequences, which is expected to significantly enhance drug development efficiency and reduce R&D costs.
- Strong Partner Network: Absci has established strategic collaborations with top pharmaceutical companies and tech-driven biology firms like Merck and PrecisionLife, which not only bolsters the credibility of its technology but also provides robust support for future drug development initiatives.
- Building Own Drug Pipeline: In addition to offering services, Absci is advancing its own pipeline of AI-designed biologic drug candidates, and if any of these projects successfully navigate clinical trials, it could yield substantial royalty income and product economics, further enhancing its market position.
- Long-Term Investment Value: Despite the challenges inherent in drug discovery, Absci's business model and technological platform have the potential to generate multiple drugs over the next decade, prompting investors to focus on its long-term growth potential rather than short-term fluctuations.
See More
Absci Leverages AI to Design Protein Drugs
- Strengthened Partnerships: Absci's strategic collaborations with Merck and Owkin validate its hybrid AI-wet lab drug platform, showcasing its potential in the biopharmaceutical sector and likely attracting further partnerships from major pharmaceutical companies.
- Technological Innovation: Absci's Integrated Drug Creation platform combines deep learning models with high-throughput wet labs, enabling the design of potential protein drugs on computers, thereby accelerating the drug discovery process and enhancing R&D efficiency.
- Clinical Outlook: Absci's long-term vision aims to rapidly transition from disease targets to viable biologic drug sequences using AI technology, which, if successful, could significantly enhance its market competitiveness and profitability, especially over the next decade.
- Risks and Challenges: Despite the innovative nature of Absci's drug discovery process, high regulatory standards and the risk of clinical failures remain significant, necessitating careful evaluation by investors regarding its future stock performance and potential returns.
See More
Analysis of Investment Opportunities in AI Stocks
- Meta Platforms Growth: Meta's revenue surged by 33% year-over-year in Q1, showcasing the strong advertising revenue potential of its social media apps, while trading at a PE ratio of 19, below the S&P 500's 22.2, indicating that its stock remains attractive, with expectations of returning to market-average pricing by the end of 2026, providing substantial returns for investors.
- Micron's Positive Outlook: Micron's stock has more than doubled since April, with analysts projecting a 193% revenue growth this year and a continued 57% growth next year, bringing revenue to $173 billion, benefiting from the memory chip shortage, demonstrating its strong competitive position in the high-end memory market, making it a solid investment consideration.
- Nebius Rapid Growth: Nebius is expected to achieve a staggering 550% revenue growth this year and 219% next year, with projections indicating a 20-fold revenue increase from 2025 to 2027, primarily driven by its neocloud platform designed for AI workloads, highlighting its immense potential in the AI sector.
- Strategic Partnerships Enhance Competitiveness: Nebius has formed significant partnerships with Meta Platforms and Nvidia, securing access to leading GPU processors, which strengthens its competitive edge in AI workflows, and despite its stock doubling since April, its ongoing growth potential makes it an investment to watch closely.
See More
Meta and Micron Among AI Stocks Still Worth Investing
- Meta's Low Valuation: Meta reported a 33% year-over-year revenue increase in Q1, yet trades at a forward P/E ratio of 19, significantly lower than the S&P 500's 22.2, indicating a substantial discount for a mature tech firm, with expectations of returning to market-average pricing by the end of 2026, potentially yielding solid returns for investors.
- Micron's Growth Potential: Micron's stock has more than doubled since April, with projected revenue growth of 193% this year and 57% next year, reaching $173 billion, benefiting from the ongoing memory chip shortage, showcasing its strong competitive position in the high-end memory market, making it a stock worth considering.
- Nebius' Incredible Growth: Nebius is expected to achieve 550% revenue growth this year and 219% next year, with projections of a 20-fold revenue increase from 2025 to 2027, driven by its neocloud platform designed for AI workloads, highlighting its significant potential in the AI sector.
- Strategic Partnerships Enhance Competitiveness: Nebius has formed key partnerships with companies like Meta and Nvidia, allowing it to access cutting-edge GPU processors ahead of competitors, further solidifying its market position in AI workflows, and despite its stock doubling, it remains an attractive investment option based on its ongoing growth potential.
See More
Nvidia Actively Expands AI Equity Investments
- Equity Investment Strategy: Nvidia is establishing a partnership with Iren, planning to acquire up to 30 million shares at $70 each over five years, representing a potential $2.1 billion investment that underscores its deep involvement in the AI data center sector.
- Strong Market Performance: Iren's stock has surged nearly 600% over the past year, currently trading around $57, with expectations to exceed $70 in five years, which would yield significant returns for Nvidia and enhance its financial health.
- Diversified Portfolio: Nvidia has also invested $5 billion in Intel by the end of 2025, benefiting from over 200% gains, reflecting its broad investment strategy aimed at enhancing overall returns through diversification in the AI industry.
- Industry Leadership: Nvidia maintains strong relationships with companies like CoreWeave, Synopsis, and Coherent, leveraging its leadership in the AI chip market to actively expand equity investments, demonstrating confidence in sustained growth and future market opportunities.
See More
Nvidia Expands Investments in AI Companies
- Equity Investment Strategy: Nvidia has secured a partnership with Iren, granting it a five-year option to purchase up to 30 million shares at $70 each, representing a potential $2.1 billion investment that could yield significant returns if Iren's stock exceeds $70 in the future.
- Market Performance Analysis: Iren's stock has surged nearly 600% over the past year, currently trading around $57, and with the anticipated expansion of AI infrastructure, its stock price could rise substantially over the next five years, enhancing Nvidia's balance sheet.
- Diversified Investment Portfolio: Nvidia invested $5 billion in Intel at $23.28 per share near the end of 2025, with Intel's stock now up over 200% year-to-date, providing Nvidia with an additional revenue stream that outpaces its own revenue growth.
- Industry Leadership Position: Nvidia's strong relationships with companies like CoreWeave, Synopsys, and Coherent further solidify its leadership in the AI chip sector, showcasing its deep understanding of smaller AI firms and negotiation capabilities, which enhance future investment potential.
See More
Absci Corp: The Future Potential of Drug Discovery
- Innovative Drug Discovery Platform: Absci Corp utilizes its Integrated Drug Creation platform to leverage generative AI for designing potential protein-based drugs, aiming to rapidly transform disease targets into viable biologic drug sequences, which is expected to significantly enhance drug development efficiency and reduce R&D costs.
- Strong Partner Network: Absci has established strategic collaborations with top pharmaceutical companies and tech-driven biology firms like Merck and PrecisionLife, which not only bolsters the credibility of its technology but also provides robust support for future drug development initiatives.
- Building Own Drug Pipeline: In addition to offering services, Absci is advancing its own pipeline of AI-designed biologic drug candidates, and if any of these projects successfully navigate clinical trials, it could yield substantial royalty income and product economics, further enhancing its market position.
- Long-Term Investment Value: Despite the challenges inherent in drug discovery, Absci's business model and technological platform have the potential to generate multiple drugs over the next decade, prompting investors to focus on its long-term growth potential rather than short-term fluctuations.
See More
Absci Leverages AI to Design Protein Drugs
- Strengthened Partnerships: Absci's strategic collaborations with Merck and Owkin validate its hybrid AI-wet lab drug platform, showcasing its potential in the biopharmaceutical sector and likely attracting further partnerships from major pharmaceutical companies.
- Technological Innovation: Absci's Integrated Drug Creation platform combines deep learning models with high-throughput wet labs, enabling the design of potential protein drugs on computers, thereby accelerating the drug discovery process and enhancing R&D efficiency.
- Clinical Outlook: Absci's long-term vision aims to rapidly transition from disease targets to viable biologic drug sequences using AI technology, which, if successful, could significantly enhance its market competitiveness and profitability, especially over the next decade.
- Risks and Challenges: Despite the innovative nature of Absci's drug discovery process, high regulatory standards and the risk of clinical failures remain significant, necessitating careful evaluation by investors regarding its future stock performance and potential returns.
See More
Analysis of Investment Opportunities in AI Stocks
- Meta Platforms Growth: Meta's revenue surged by 33% year-over-year in Q1, showcasing the strong advertising revenue potential of its social media apps, while trading at a PE ratio of 19, below the S&P 500's 22.2, indicating that its stock remains attractive, with expectations of returning to market-average pricing by the end of 2026, providing substantial returns for investors.
- Micron's Positive Outlook: Micron's stock has more than doubled since April, with analysts projecting a 193% revenue growth this year and a continued 57% growth next year, bringing revenue to $173 billion, benefiting from the memory chip shortage, demonstrating its strong competitive position in the high-end memory market, making it a solid investment consideration.
- Nebius Rapid Growth: Nebius is expected to achieve a staggering 550% revenue growth this year and 219% next year, with projections indicating a 20-fold revenue increase from 2025 to 2027, primarily driven by its neocloud platform designed for AI workloads, highlighting its immense potential in the AI sector.
- Strategic Partnerships Enhance Competitiveness: Nebius has formed significant partnerships with Meta Platforms and Nvidia, securing access to leading GPU processors, which strengthens its competitive edge in AI workflows, and despite its stock doubling since April, its ongoing growth potential makes it an investment to watch closely.
See More
Meta and Micron Among AI Stocks Still Worth Investing
- Meta's Low Valuation: Meta reported a 33% year-over-year revenue increase in Q1, yet trades at a forward P/E ratio of 19, significantly lower than the S&P 500's 22.2, indicating a substantial discount for a mature tech firm, with expectations of returning to market-average pricing by the end of 2026, potentially yielding solid returns for investors.
- Micron's Growth Potential: Micron's stock has more than doubled since April, with projected revenue growth of 193% this year and 57% next year, reaching $173 billion, benefiting from the ongoing memory chip shortage, showcasing its strong competitive position in the high-end memory market, making it a stock worth considering.
- Nebius' Incredible Growth: Nebius is expected to achieve 550% revenue growth this year and 219% next year, with projections of a 20-fold revenue increase from 2025 to 2027, driven by its neocloud platform designed for AI workloads, highlighting its significant potential in the AI sector.
- Strategic Partnerships Enhance Competitiveness: Nebius has formed key partnerships with companies like Meta and Nvidia, allowing it to access cutting-edge GPU processors ahead of competitors, further solidifying its market position in AI workflows, and despite its stock doubling, it remains an attractive investment option based on its ongoing growth potential.
See More
Nvidia Actively Expands AI Equity Investments
- Equity Investment Strategy: Nvidia is establishing a partnership with Iren, planning to acquire up to 30 million shares at $70 each over five years, representing a potential $2.1 billion investment that underscores its deep involvement in the AI data center sector.
- Strong Market Performance: Iren's stock has surged nearly 600% over the past year, currently trading around $57, with expectations to exceed $70 in five years, which would yield significant returns for Nvidia and enhance its financial health.
- Diversified Portfolio: Nvidia has also invested $5 billion in Intel by the end of 2025, benefiting from over 200% gains, reflecting its broad investment strategy aimed at enhancing overall returns through diversification in the AI industry.
- Industry Leadership: Nvidia maintains strong relationships with companies like CoreWeave, Synopsis, and Coherent, leveraging its leadership in the AI chip market to actively expand equity investments, demonstrating confidence in sustained growth and future market opportunities.
See More
Nvidia Expands Investments in AI Companies
- Equity Investment Strategy: Nvidia has secured a partnership with Iren, granting it a five-year option to purchase up to 30 million shares at $70 each, representing a potential $2.1 billion investment that could yield significant returns if Iren's stock exceeds $70 in the future.
- Market Performance Analysis: Iren's stock has surged nearly 600% over the past year, currently trading around $57, and with the anticipated expansion of AI infrastructure, its stock price could rise substantially over the next five years, enhancing Nvidia's balance sheet.
- Diversified Investment Portfolio: Nvidia invested $5 billion in Intel at $23.28 per share near the end of 2025, with Intel's stock now up over 200% year-to-date, providing Nvidia with an additional revenue stream that outpaces its own revenue growth.
- Industry Leadership Position: Nvidia's strong relationships with companies like CoreWeave, Synopsys, and Coherent further solidify its leadership in the AI chip sector, showcasing its deep understanding of smaller AI firms and negotiation capabilities, which enhance future investment potential.
See More
